Anthony Economou Optimistic About New Glaucoma Trials

NEW YORK, NY, September 10, 2012 (Press-News.org) As a leading ophthalmologist in Tulsa, Okla., Dr. Anthony Economou specializes in the treatment of glaucoma. With a vast understanding of the eye disease that affects the optic nerve, Economou notes that management of glaucoma is imperative for sustained vision. However, adequate treatment can become complicated among patients who do not realize the severity of the disease or have trouble delivering medicated eye drops. A recent article from MHT reveals a new medical device that may provide assistance to these types of patients if approved and released into the market.

According to the article, Ocular Therapeutix entered the second phase of its trial testing for a "so-called punctum plug." It states that the medical device "can be inserted near the eye, to deliver a sustained release dose of an existing drug, travoprost, to treat ocular hypertension...and glaucoma." The article notes that glaucoma afflicts approximately 2 million Americans, and while the disease develops under slow progression and does not cause pain, it can cause blindness if not properly treated. For these reasons, Anthony Economou notes that it is essential for patients who are prescribed travoprost drops to make sure they are delivered regularly and in proper doses.

In the article Amar Sawhney, president and CEO of Ocular Therapeutix, explains why his company's new product could help a large portion of glaucoma patients. He states, "Older patients may have difficulty administering drugs for themselves. They may put in too much medication or too little medication. Or, since glaucoma is a silent disease, patients don't feel the need to consistently take their drops, which over time will cause worsening of their vision, and may even lead to blindness. Therefore, something which is administered consistently without relying on patient administration is important."

In agreement, Anthony Economou responds, noting that he could see the new device to be effective among his patients. He comments, "I have many arthritic patients who can benefit from a drug delivery system that does not depend on hand dexterity. It would also help in the cost maintenance for patients who have difficultly self-dosing drops due to waste." As the article states, Ocular plans on beginning the third phase of the trial in 2013, with an anticipated product launch in 2015.

ABOUT:

With 17 years of experience, Anthony Economou DO PC specializes in refractive errors and the management of glaucoma. Dr. Anthony Economou is certified in ophthalmology by the American Osteopathic Board of Ophthalmology and Otorhinolaryngology. In addition, Dr. Economou focuses on preventative health practices and is a Doctor of Osteopathic Medicine. Anthony Economou currently practices as part of the Ophthalmology Consultants of Tulsa. He has served the Tulsa community professionally for 15 years and has familial ties to the area.

Website: http://anthonyeconomou.net/